Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study
This article was originally published in The Gray Sheet
Executive Summary
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial
You may also be interested in...
Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study
Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm
Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study
Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm
Drug-Eluting Stent Cost-Effectiveness Potential Realized In Real World
Analysis of randomized clinical trials and Medicare cost data confirm earlier predictions that drug-eluting stents are cost-effective, according to David Cohen, MD, Beth Israel Deaconess Hospital